|
Free Research Articles
Citations 1-10 of 526 total displayed.
|
Most recent content
(15 Oct 2008):
|
The GPIIb/IIIa (integrin  IIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend
- Barry S. Coller and Sanford J. Shattil
Blood 2008; 112: 3011-3025.
[Abstract]
[Full text]
[PDF]
Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring
- Ye-Xiong Li, Hui Fang, Qing-Feng Liu, Jiade Lu, Shu-Nan Qi, Hua Wang, Jing Jin, Wei-Hu Wang, Yue-Ping Liu, Yong-Wen Song, Shu-Lian Wang, Xin-Fan Liu, Xiao-Li Feng, and Zi-Hao Yu
Blood 2008; 112: 3057-3064.
[Abstract]
[Full text]
[PDF]
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories
- Régis Peffault de Latour, Jean Yves Mary, Célia Salanoubat, Louis Terriou, Gabriel Etienne, Mohamad Mohty, Sophie Roth, Sophie de Guibert, Sebastien Maury, Jean Yves Cahn, and Gerard Socié, on behalf of the French Society of Hematology and of the French Association of Young Hematologists
Blood 2008; 112: 3099-3106.
[Abstract]
[Full text]
[PDF]
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- Antonio Palumbo, Sara Bringhen, Anna M. Liberati, Tommaso Caravita, Antonietta Falcone, Vincenzo Callea, Marco Montanaro, Roberto Ria, Antonio Capaldi, Renato Zambello, Giulia Benevolo, Daniele Derudas, Fausto Dore, Federica Cavallo, Francesca Gay, Patrizia Falco, Giovannino Ciccone, Pellegrino Musto, Michele Cavo, and Mario Boccadoro
Blood 2008; 112: 3107-3114.
[Abstract]
[Full text]
[PDF]
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
- Bart Barlogie, Frits van Rhee, John D. Shaughnessy, Jr, Joshua Epstein, Shmuel Yaccoby, Mauricio Pineda-Roman, Klaus Hollmig, Yazan Alsayed, Antje Hoering, Jackie Szymonifka, Elias Anaissie, Nathan Petty, Naveen S. Kumar, Geetika Srivastava, Bonnie Jenkins, John Crowley, and Jerome B. Zeldis
Blood 2008; 112: 3122-3125.
[Abstract]
[Full text]
[PDF]
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
- Miguel A. Sanz, Pau Montesinos, Edo Vellenga, Consuelo Rayón, Javier de la Serna, Ricardo Parody, Juan M. Bergua, Angel León, Silvia Negri, Marcos González, Concha Rivas, Jordi Esteve, Gustavo Milone, José D. González, Elena Amutio, Salut Brunet, J. García-Laraña, Dolors Colomer, María J. Calasanz, Carmen Chillón, Eva Barragán, Pascual Bolufer, and Bob Lowenberg
Blood 2008; 112: 3130-3134.
[Abstract]
[Full text]
[PDF]
|
Past content
(since May 2004):
|
Heparin-induced thrombocytopenia: a historical perspective
- John G. Kelton and Theodore E. Warkentin
Blood 2008; 112: 2607-2616.
[Full text]
[PDF]
The hazards of blood transfusion in historical perspective
- Harvey J. Alter and Harvey G. Klein
Blood 2008; 112: 2617-2626.
[Abstract]
[Full text]
[PDF]
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease
- Mary E. D. Flowers, Jane F. Apperley, Koen van Besien, Ahmet Elmaagacli, Andrew Grigg, Vijay Reddy, Andrea Bacigalupo, Hans-Jochem Kolb, Luis Bouzas, Mauricette Michallet, H. Miles Prince, Robert Knobler, Dennis Parenti, Jose Gallo, and Hildegard T. Greinix
Blood 2008; 112: 2667-2674.
[Abstract]
[Full text]
[PDF]
High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE)
- Alanna M. Chamberlain, Aaron R. Folsom, Susan R. Heckbert, Wayne D. Rosamond, and Mary Cushman
Blood 2008; 112: 2675-2680.
[Abstract]
[Full text]
[PDF]
|
|
